Barclays Downgrades CinCor Pharma to Equal-Weight, Raises Price Target to $31
Barclays analyst Leon Wang downgrades CinCor Pharma (NASDAQ:CINC) from Overweight to Equal-Weight and raises the price target from $22 to $31.
Morgan Stanley Maintains Equal-Weight on CinCor Pharma, Raises Price Target to $30
Morgan Stanley analyst Jeffrey Hung maintains CinCor Pharma (NASDAQ:CINC) with a Equal-Weight and raises the price target from $22 to $30.
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday.
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday.
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session.
US Stocks Open Higher; Dow Rises 150 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday.
Analyzing CinCor Pharma’s Short Interest
CinCor Pharma's (NASDAQ:CINC) short percent of float has risen 4.28% since its last report. The company recently reported that it has 2.25 million shares sold short, which is 8.78% of all regular shares that are available for trading.
Barclays Initiates Coverage On CinCor Pharma with Overweight Rating, Announces Price Target of $22
Barclays analyst Leon Wang initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Overweight rating and announces Price Target of $22.
